Posted by Michael Wonder on 14 Sep 2021
Limiting the impact on Kiwis as API leaves the NZ market
14 September 2021 - PHARMAC is working hard to limit the impact on over 1 million Kiwis who currently take funded API Consumer Brands medicines, following their announcement that they are leaving the New Zealand market.
API announced in July this year they are closing their Auckland manufacturing plant and withdrawing from the New Zealand pharmaceutical market in 2022/23.
API supplies around 21 funded medicines in New Zealand, including treatments used to manage pain, epilepsy, ADHD, and skin irritations.
